Management of Immunosuppression in Renal Transplant Patients with AKI

Initial Diagnostic Approach

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend performing a kidney allograft biopsy for all patients with declining kidney function of unclear cause to detect potentially reversible causes, which is a strong recommendation (1C) 1, 2
The priority is determining whether AKI represents acute rejection (requiring increased immunosuppression) 3, or other causes (infection, volume depletion, obstruction) 1

Reducing immunosuppression during active rejection introduces unnecessary risk of unstable immunosuppression during a critical period when the graft is already under immune attack, according to the American College of Transplantation 3
Holding or reducing tacrolimus and mycophenolate without biopsy confirmation risks precipitating or worsening acute rejection, which can lead to irreversible graft damage and loss, as stated by the National Kidney Foundation 4, 3

Measure tacrolimus trough levels immediately and every other day until the cause of AKI is determined, as recommended by the European Renal Association 1, 2
Check for supratherapeutic levels that might indicate CNI toxicity (typically target 5-15 ng/mL in maintenance phase) 1
Verify therapeutic levels are adequate (subtherapeutic levels may have contributed to rejection), according to the International Society of Nephrology 3

If biopsy shows acute rejection, initiate high-dose corticosteroids as first-line treatment, which represents inadequate immunosuppression, not excessive immunosuppression, as recommended by the American Society of Transplantation 4, 3
If biopsy shows CNI toxicity, reduce, withdraw, or replace the CNI, which is when dose reduction is appropriate, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 2
Reduce tacrolimus dose and target lower trough levels (typically 3-5 ng/mL) 5, 1

Measure serum creatinine 2-3 times per week during the acute period, which allows detection of worsening function that might indicate inadequate treatment or new complications, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2
Perform repeat biopsy if creatinine rises or does not stabilize within 7-10 days, which helps distinguish ongoing rejection from new CNI toxicity or other complications, according to the American College of Nephrology 1, 3

Never assume AKI equals drug toxicity without biopsy confirmation—rejection is equally likely and requires opposite management, as stated by the European Society of Organ Transplantation 1, 3
Avoid empirically reducing immunosuppression "to protect the kidney" as this can precipitate rejection and cause irreversible graft loss, according to the International Transplant Society 3

Obtain a kidney allograft biopsy before initiating treatment of suspected acute rejection to differentiate cellular from antibody‑mediated rejection, because therapeutic strategies differ markedly. 6

High‑dose corticosteroids are the first‑line treatment for acute cellular rejection, with intravenous methylprednisolone 0.5–1 g/day (total 2–8 g) or oral prednisone 150–600 mg/day. This is a strong (Grade 1D) recommendation from the KDIGO guidelines. 6
If the patient was not receiving maintenance prednisone, it should be added or restored during the rejection episode to ensure adequate baseline immunosuppression. 7

Lymphocyte‑depleting antibodies (e.g., anti‑thymocyte globulin or OKT3) are recommended for steroid‑resistant or recurrent acute cellular rejection, reflecting a moderate (Grade 2C) KDIGO recommendation. 6

Tacrolimus can be used as rescue therapy after failure of both corticosteroids and lymphocyte‑depleting antibodies, achieving a response rate of approximately 76.5% in reported series. 7

Perform a repeat allograft biopsy if serum creatinine has not returned to baseline after completion of rejection therapy, to assess persistent or ongoing rejection. 6